Tetra Bio-Pharma Inc. appoints new Chief Financial Officer
by CM Staff
Ms. Auld is a Financial Executive with a background in Canadian and U.S. publicly listed companies in the pharmaceutical and diagnostic technology industries.
OTTAWA — Tetra Bio-Pharma Inc., a company involved in cannabinoid-derived drug discovery and development, announces the appointment of Leslie Auld, H.BSc, MBA, CPA, as Chief Financial Officer and member of the Company’s executive team, effective May 30, 2022.
Ms. Auld is a Financial Executive with a background in Canadian and U.S. publicly listed companies in the pharmaceutical and diagnostic technology industries. She has held executive positions in biotechnology companies developing investigational new drugs, which is the core activity of Tetra.
Ms. Auld is a finance professional who reportedly combines strong planning, organizational, and communication skills with an ability to lead operations and interact with senior management and Board of Directors.
“We were very fortunate to find a CFO with experience in Canadian TSX-listed biotechnology companies. Leslie has all the skills needed to bring Tetra to its next phase of growth. I look forward to working with Leslie through these difficult market conditions to build Tetra into a successful pharmaceutical company,” said Dr. Chamberland, CEO.
Tetra Bio-Pharma is involved in cannabinoid-derived drug discovery and development with a FDA and a Health Canada cleared clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers.
